Cargando…

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data

PURPOSE: This study evaluates whether gene signatures for chemosensitivity for irinotecan and 5-fluorouracil (5-FU) derived from in vitro grown cancer cell lines can predict clinical sensitivity to these drugs. METHODS: To test if an irinotecan signature and a SN-38 signature could identify patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buhl, Ida Kappel, Gerster, Sarah, Delorenzi, Mauro, Jensen, Thomas, Jensen, Peter Buhl, Bosman, Fred, Tejpar, Sabine, Roth, Arnaud, Brunner, Nils, Hansen, Anker, Knudsen, Steen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865183/ https://www.ncbi.nlm.nih.gov/pubmed/27171152 http://dx.doi.org/10.1371/journal.pone.0155123

Ejemplares similares

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
por: Buhl, Ida Kappel, et al.
Publicado: (2018)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
por: Popovici, Vlad, et al.
Publicado: (2013)

Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer
por: Winther, Mette, et al.
Publicado: (2016)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014)

Batch Effect Confounding Leads to Strong Bias in Performance Estimates Obtained by Cross-Validation
por: Soneson, Charlotte, et al.
Publicado: (2014)

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
por: Buhl, Anna Sofie Kappel, et al.
Publicado: (2018)

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
por: Budinska, Eva, et al.
Publicado: (2013)

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2017)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
por: Kikuchi, Koji, et al.
Publicado: (2022)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients
por: Knudsen, Steen, et al.
Publicado: (2014)

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
por: Lin, Xue, et al.
Publicado: (2015)

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
por: Van Cutsem, E, et al.
Publicado: (2005)

A Comprehensive Characterization of Genome-Wide Copy Number Aberrations in Colorectal Cancer Reveals Novel Oncogenes and Patterns of Alterations
por: Xie, Tao, et al.
Publicado: (2012)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
por: Tejpar, Sabine, et al.
Publicado: (2010)

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
por: Jandu, Haatisha, et al.
Publicado: (2016)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017)

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis
por: Chen, Ke, et al.
Publicado: (2016)

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
por: Mabro, M, et al.
Publicado: (2006)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
por: Macarulla Mercadé, Teresa, et al.
Publicado: (2020)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

On the Pathological Anatomy of Puerperal Fever
por: Buhl,
Publicado: (1862)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
por: Akhoundova Sanoyan, Dilara, et al.
Publicado: (2020)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

Digital education for health professionals in India: a scoping review of the research
por: Jensen, Lasse X, et al.
Publicado: (2023)

Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
por: Andersen, Henrik, et al.
Publicado: (2020)

Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL
por: Knudsen, Steen, et al.
Publicado: (2015)

Reduced survival of total knee arthroplasty after previous unicompartmental knee arthroplasty compared with previous high tibial osteotomy: a propensity-score weighted mid-term cohort study based on 2,133 observations from the Danish Knee Arthroplasty Registry
por: El-Galaly, Anders, et al.
Publicado: (2020)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Journal of Insect Science - Front Cover
por: Buhl, Christine
Publicado: (2017)

Interpretable Clinical Decision Support System for Audiology Based on Predicted Common Audiological Functional Parameters (CAFPAs)
por: Buhl, Mareike
Publicado: (2022)

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
por: Taal, B G, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_g8tad678o245na2h3u5buh9gav